Skip to search formSkip to main contentSkip to account menu

PM02734

Known as: Depsipeptide PM02734 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
This first-in-human, phase I clinical trial was designed to determine the dose-limiting toxicities (DLTs) and the dose for phase… 
2013
2013
Elisidepsin (PM02734, Irvalec®) is a synthetic marine-derived cyclic peptide of the Kahalalide F family currently in phase II… 
2012
2012
PurposeTo determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and recommended phase II dose (RD) of… 
Highly Cited
2011
Highly Cited
2011
Purpose: PM02734 (elisidepsin) is a synthetic marine-derived cyclic peptide of the kahalalide family currently in phase II… 
Review
2009
Review
2009
Because of the poor results observed after platinum-based first-line chemotherapy, research on new strategies for second-line… 
2008
2008
PM02734 is a novel synthetic antitumor drug that is currently in phase I clinical trials. To gain some insight into its mode of… 
2008
2008
2513 Background: PM02734 is a chemically synthesized depsipeptide with a broad spectrum of activity against solid tumors in vitro… 
2006
2006
A rapid and sensitive liquid chromatography/tandem mass spectrometry (LC/MS/MS) assay was developed and validated to quantify a… 
2006
2006
4712 The novel investigational agent PM02734 is a member of the Kahalalide F family of compounds that display marked anttumor…